Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Aviance Capital Partners LLC

Aviance Capital Partners LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 49.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,206 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Aviance Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $1,573,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. CNB Bank bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Pacific Center for Financial Services lifted its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $28,000. Bell Investment Advisors Inc grew its holdings in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. Finally, Tyler Stone Wealth Management raised its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.2 %

NVO traded up $1.52 on Monday, reaching $124.57. 3,634,935 shares of the company traded hands, compared to its average volume of 4,848,793. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The company has a market cap of $559.01 billion, a price-to-earnings ratio of 42.96, a PEG ratio of 1.93 and a beta of 0.43. The stock’s 50 day moving average price is $127.22 and its 200-day moving average price is $113.29.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on NVO shares. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.